Trulicity Medicare Part D Coverage: What You Actually Pay in 2026

How Medicare Part D Classifies Trulicity

Medicare Part D plans place Trulicity on their formulary as a brand-name injectable, most often at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier placement determines your coinsurance rate. A Tier 3 listing typically means 25-33% coinsurance after deductible, while Tier 4 may run 33-50%.

The Centers for Medicare & Medicaid Services (CMS) requires all Part D sponsors to cover at least two drugs in every pharmacologic class, and the GLP-1 receptor agonist class has enough approved agents that plans have negotiating use 1. This means some plans may prefer semaglutide (Ozempic) or liraglutide (Victoza) over Trulicity, or vice versa, depending on the rebate agreements Eli Lilly has negotiated with each plan's pharmacy benefit manager.

Check your specific plan's formulary on Medicare.gov's Plan Finder before assuming Trulicity is covered at a preferred tier. Plans update their formularies annually, and mid-year changes can shift a drug from preferred to non-preferred status with 30 days' notice. If Trulicity moves to a higher tier or off formulary entirely, you have the right to request a formulary exception through your plan's coverage determination process 2.

The distinction between Tier 3 and Tier 4 matters less than it did before 2025, because the $2,000 annual cap now limits total exposure regardless of coinsurance percentage. But tier placement still affects how quickly you reach that cap and what your monthly installments look like under the Medicare Prescription Payment Plan.

The $2,000 Annual Cap and What It Means for Trulicity Users

The Inflation Reduction Act (IRA) introduced a hard $2,000 annual out-of-pocket cap for Part D beneficiaries starting in 2025, eliminating the previous catastrophic coverage phase where patients still owed 5% coinsurance indefinitely 3. This single change is the most significant cost protection Medicare has ever offered for expensive brand-name drugs.

Here is the math for a Trulicity user. At $931 per month list price, a beneficiary paying 25% coinsurance after a $590 deductible would accumulate roughly $233 per fill in true out-of-pocket costs. That means you hit the $2,000 cap within approximately 6-7 months of fills. After that point, you owe $0 for Trulicity for the remainder of the calendar year.

Before the IRA, a Part D enrollee using Trulicity could have spent $4,000-$5,000 or more annually, depending on plan design and whether they qualified for any gap coverage. The cap cut that exposure by more than half.

One nuance: the $2,000 figure is indexed to Part D per-capita spending growth, so CMS may adjust it upward in future years. For 2026, the cap remains $2,000 4. Premiums, however, do not count toward the cap. Only deductible payments, copays, and coinsurance applied at the pharmacy counter accumulate toward the threshold.

The Medicare Prescription Payment Plan

Starting in 2025, CMS introduced the Medicare Prescription Payment Plan (M3P), which allows beneficiaries to spread their out-of-pocket drug costs across monthly installments rather than paying large sums at the pharmacy counter during the first months of the year 5.

For Trulicity users, this is practical. Instead of paying $233 per fill for the first several months until you hit $2,000, you can opt into the M3P and pay roughly $167 per month ($2,000 divided by 12) for the entire year. No interest. No credit check.

Enrollment is voluntary and can happen at any time during the plan year. You contact your Part D plan directly to opt in. If you join mid-year, the remaining balance is spread across the months left. This program does not reduce your total spending. It smooths it.

Dr. Stacie Dusetzina, a health policy researcher at Vanderbilt University Medical Center, has noted that "the payment plan is designed to prevent the January shock that causes many Medicare beneficiaries to abandon their medications in the first quarter of the year." That pattern of early-year abandonment has been documented in pharmacy claims data, where adherence to GLP-1 agonists drops measurably in Q1 when cost-sharing is highest 6.

Why Eli Lilly's Savings Card Does Not Work with Medicare

Eli Lilly offers a Trulicity Savings Card for commercially insured patients that can reduce copays to as low as $25 per fill. This program is explicitly unavailable to anyone enrolled in a federal healthcare program, including Medicare Part D, Medicaid, Tricare, or VA benefits 7. Federal anti-kickback statutes prohibit pharmaceutical manufacturers from offering copay assistance to government-insured beneficiaries, with narrow exceptions for vaccines and certain Part B drugs.

This restriction catches many patients off guard. A beneficiary who turns 65 and transitions from employer coverage to Medicare may lose access to a savings card that previously reduced their Trulicity cost to $25 per month. The result can be a sudden jump to hundreds of dollars per fill, at least until the $2,000 cap is reached.

There is no legal workaround. Patient assistance foundations that help with copays for Medicare enrollees must operate independently from the manufacturer and cannot restrict their funds to a single drug. The Lilly Cares Foundation does offer free Trulicity to qualifying uninsured or underinsured patients, but Medicare enrollment generally disqualifies applicants because they are considered "insured" 8.

Extra Help (Low-Income Subsidy): The Strongest Medicare Discount

The Part D Extra Help program, also called the Low-Income Subsidy (LIS), is the single most powerful cost-reduction tool for Medicare beneficiaries who need Trulicity. Full Extra Help eliminates the deductible, reduces copays to $0 for generic drugs and $4.50-$11.20 for brand-name drugs per fill (2026 amounts), and eliminates the coverage gap entirely 9.

Eligibility expanded under the IRA. Previously, partial Extra Help was available to beneficiaries with incomes between 135% and 150% of the federal poverty level (FPL). Starting in 2024, the full subsidy extends to everyone under 150% FPL, eliminating the partial benefit tier.

For a single individual in 2026 to 150% FPL is approximately $23 to 595 in annual income (this figure adjusts annually). Asset limits also apply but exclude your home, one vehicle, and burial funds.

If you qualify for full Extra Help, your monthly Trulicity cost drops from hundreds of dollars to $11.20 or less. That is a reduction of over 95% from the cash price. Application is free through the Social Security Administration (SSA) at ssa.gov or by calling 1-800-772-1213. Many state Health Insurance Assistance Programs (SHIPs) will help with the application at no charge.

According to CMS data, approximately 13 million Medicare beneficiaries qualify for Extra Help, but an estimated 2-3 million eligible individuals are not enrolled 10. If you are taking a drug that costs $931 per month, checking your eligibility should be the first step, not the last.

State Pharmaceutical Assistance Programs (SPAPs)

Twenty-three states and the U.S. Virgin Islands operate State Pharmaceutical Assistance Programs that supplement Medicare Part D coverage 11. These programs vary widely in eligibility and benefit design, but many cover Part D cost-sharing for residents who earn too much for Extra Help but still struggle with brand-name drug costs.

Programs like New York EPIC, Pennsylvania PACE, and Connecticut ConnPACE have income thresholds between 200% and 400% FPL. Some pay a portion of your Part D premium. Others cover copays directly. A few provide wrap-around coverage that effectively eliminates out-of-pocket costs for formulary drugs.

Your State Health Insurance Assistance Program (SHIP) can identify whether your state offers an SPAP and help with enrollment. SHIP counselors provide free, unbiased assistance and are funded by CMS. Find your local SHIP at shiphelp.org or by calling 1-877-839-2675.

Not every SPAP covers all Part D drugs. Some maintain their own formularies. Confirm that Trulicity (or dulaglutide) appears on the program's drug list before counting on the benefit.

Requesting a Tier Exception or Prior Authorization Override

If your Part D plan places Trulicity on a non-preferred tier (Tier 4 or higher), you can request a tier exception to have it covered at the preferred brand copay level. CMS requires plans to grant exceptions when the prescriber demonstrates that the preferred alternatives are medically inappropriate for the patient 12.

The process works like this. Your prescriber submits a coverage determination request to the plan, including clinical documentation that explains why preferred-tier GLP-1 agonists (often semaglutide or liraglutide) are not suitable. Valid reasons include prior adverse reactions, contraindications, treatment failure with the preferred agent, or drug interactions.

Plans must respond within 72 hours for standard requests and 24 hours for expedited requests. If denied, you can appeal through a five-level process that eventually reaches an administrative law judge and federal court. In practice, most successful exceptions are resolved at the first or second level.

The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced major adverse cardiovascular events by 12% compared to placebo over a median 5.4 years in patients with type 2 diabetes and cardiovascular risk factors (HR 0.88 to 95% CI 0.79-0.99) 13. This cardiovascular benefit, which led to an expanded FDA indication, provides strong clinical justification for a tier exception when a plan prefers a GLP-1 agonist without similar cardiovascular outcome data.

Dr. John Buse, Director of the Diabetes Center at the University of North Carolina School of Medicine, has stated: "The cardiovascular benefits demonstrated in REWIND apply to a broader population than most other GLP-1 agonist trials, including patients without established cardiovascular disease." This broader applicability can support exception requests for primary prevention patients.

Comparing Part D Costs Across Plans During Open Enrollment

Annual open enrollment (October 15 through December 7) is the window to switch Part D plans. The Medicare Plan Finder at medicare.gov allows you to enter your specific drugs, doses, and preferred pharmacy to compare estimated annual costs across every plan available in your ZIP code.

Two plans in the same region can produce dramatically different annual costs for the same drug. A 2023 analysis published in JAMA Internal Medicine found that Part D out-of-pocket costs for the same GLP-1 agonist varied by more than $1,500 annually between the lowest-cost and highest-cost plans in the same geographic area 14.

When comparing plans for Trulicity coverage, look beyond the monthly premium. Evaluate these four factors together:

The annual deductible (ranges from $0 to $590 in 2026). The tier placement of Trulicity on that plan's formulary. Whether the plan applies coinsurance (a percentage) or a flat copay. Any quantity limits, step therapy requirements, or prior authorization that could delay or restrict access.

A plan with a $40 monthly premium and Tier 4 placement may cost more over the year than a plan with a $60 monthly premium and Tier 3 placement. The Plan Finder calculates this automatically when you input your prescriptions.

Dulaglutide Clinical Profile: Why Prescribers Choose It

Trulicity received FDA approval in September 2014 for adults with type 2 diabetes mellitus as an adjunct to diet and exercise 15. It is available in five dose strengths: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg, each administered once weekly via a single-dose prefilled pen.

The AWARD trial program, spanning more than 10 clinical studies, established dulaglutide's efficacy and safety profile. AWARD-1 (N=978) showed that dulaglutide 1.5 mg reduced HbA1c by 1.51% from baseline at 26 weeks, compared to 0.99% with exenatide twice daily and 0.46% with placebo 16.

Dulaglutide's once-weekly dosing and no dose-titration requirement at the 0.75 mg starting dose make it a practical choice for patients who prefer simplicity. The pen device does not require manual needle attachment or dial setting. You press it against the skin and click a button. The entire injection takes about 5 seconds.

Weight loss with dulaglutide is modest compared to semaglutide. In the AWARD-11 trial (N=1,842), the 4.5 mg dose produced approximately 4.6 kg mean weight loss at 36 weeks 17. By comparison, semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks in STEP-1 (N=1,961) 18. This difference matters for patients whose primary goal is weight management, but for patients focused on glycemic control and cardiovascular risk reduction, dulaglutide remains a well-supported option.

What About Compounded Dulaglutide?

As of May 2026, compounded dulaglutide is not commercially available. Unlike semaglutide, which has been compounded by 503A and 503B pharmacies during shortage periods, dulaglutide's molecular complexity as a fusion protein makes compounding impractical with current pharmacy-level technology 19.

The FDA's position on compounding GLP-1 receptor agonists has tightened since 2024, with enforcement actions against pharmacies compounding semaglutide after Novo Nordisk's shortage status was resolved. No equivalent shortage designation exists for Trulicity, which means even the regulatory pathway that temporarily permitted semaglutide compounding does not apply to dulaglutide.

Patients searching for cheaper alternatives to brand Trulicity should focus on formulary optimization, Extra Help enrollment, SPAPs, and annual plan comparison rather than compounded products. No FDA-approved generic or biosimilar version of dulaglutide exists as of this writing.

Switching GLP-1 Agonists to Reduce Part D Costs

If your Part D plan strongly prefers a different GLP-1 agonist over Trulicity, switching may reduce your costs. Plans that place semaglutide (Ozempic) at Tier 3 and Trulicity at Tier 4 will charge less for the preferred option. The clinical switch is straightforward: both are once-weekly injectables with overlapping dose ranges.

The 2024 American Diabetes Association Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit as preferred agents for patients with type 2 diabetes and established atherosclerotic cardiovascular disease or high cardiovascular risk 20. Both dulaglutide and semaglutide carry cardiovascular benefit indications, so switching between them does not sacrifice evidence-based care.

Discuss any formulary-driven switch with your prescriber. Dose equivalence is not one-to-one. A patient on dulaglutide 1.5 mg would typically start semaglutide at 0.25 mg and titrate over 8-16 weeks, which means a temporary period of less-than-maximal glycemic control during the transition.